Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check6 days agoChange DetectedAdded the Locations section with new site codes (AV, BA, FI, FO, ME, MI, MO, PA, PD, PG, PI, PR, RE, RM, RO, Torino) and removed individual Location subsections; updated Revision to v3.3.3.SummaryDifference1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed as part of a site version update. This change affects only revision metadata and does not alter any study details, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check35 days agoChange DetectedThe page revision label updated from v3.2.0 to v3.3.1; no substantive study content was modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check42 days agoChange DetectedRemoved the government funding lapse notice that warned the information may not be up to date and that transactions might be delayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check56 days agoChange DetectedThe observed updates are minor UI and content formatting changes that do not alter core study details (eligibility criteria, endpoints, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check85 days agoChange DetectedUpgraded to version v3.2.0 with a funding-status notice about operational limitations; v3.1.0 was removed. Indicates a maintenance/availability update rather than new content.SummaryDifference4%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.